HC Wainwright & Co. Reiterates Buy on BioLine Rx, Maintains $21 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on BioLine Rx (NASDAQ:BLRX) and maintained a price target of $21.
May 29, 2024 | 2:24 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on BioLine Rx and maintained a price target of $21.
The reiteration of a Buy rating and a maintained price target of $21 by HC Wainwright & Co. is a positive signal for investors, likely boosting short-term confidence and potentially driving the stock price up.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100